RecruitingSCI - Spinal Cord Injury
Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
Eligible age
18–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Sponsor: Shirley Ryan AbilityLab
You may qualify if…
- ✓ Male and females between ages 18-85 years
- ✓ SCI 6 months post injury
- ✓ Spinal Cord injury at or above L2
- ✓ ASIA A, B, C, or D, complete or incomplete
- ✓ The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles
You may not qualify if…
- ✕ Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease
- ✕ Any history of renal impairment
- ✕ Any debilitating disease prior to the SCI that caused exercise intolerance
- ✕ Premorbid, ongoing major depression or psychosis, altered cognitive status
- ✕ History of head injury or stroke
- ✕ Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
- ✕ History of seizures or epilepsy
- ✕ Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)
Where it's recruiting
Illinois
Chicago
Source: ClinicalTrials.gov · NCT06853015 · last updated 2026-06-03